Evidence map›Paper›PMID 28539924›Full record

ReviewFrontiers in immunology2017

Therapeutic Development of Mesenchymal Stem Cells or Their Extracellular Vesicles to Inhibit Autoimmune-Mediated Inflammatory Processes in Systemic Lupus Erythematosus.

Juhi Sharma, Jeffrey M Hampton, Giancarlo R Valiente, Takuma Wada, Holly Steigelman, Matthew C Young, Rachel R Spurbeck, Alisa D Blazek, Steffi Bösh, Wael N Jarjour and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. [Regulatory effects of mesenchymal stem cells on B1 cells and Tfh cells in children with systemic lupus erythematosus].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Extracellular Vesicles Derived FromFrontiers in immunology · 2022
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Therapeutic Application of Exosomes in Inflammatory Diseases.International journal of molecular sciences · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Juhi SharmaDivision of Rheumatology and Immunology, Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
Jeffrey M HamptonDivision of Rheumatology and Immunology, Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
Giancarlo R ValienteDivision of Rheumatology and Immunology, Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
Takuma WadaDivision of Rheumatology and Immunology, Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
Holly SteigelmanDivision of Rheumatology and Immunology, Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
Matthew C YoungThe Inflammation Foundation, Orlando, FL, USA.
Rachel R SpurbeckBattelle Memorial Institute, Columbus, OH, USA.
Alisa D BlazekBattelle Memorial Institute, Columbus, OH, USA.
Steffi BöshUniversité de Nantes, Immuno-endocrinologie Cellulaire et Moléculaire, Nantes, France.
Wael N JarjourDivision of Rheumatology and Immunology, Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
Nicholas A YoungDivision of Rheumatology and Immunology, Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
The Ohio State University Wexner Medical Center · USBattelle · USInflammation Research Foundation · USNantes Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since being discovered over half a century ago, mesenchymal stem cells (MSCs) have been investigated extensively to characterize their cellular and physiological influences. MSCs have been shown to possess immunosuppressive capacity through inhibiting lymphocyte activation/proliferation and proinflammatory cytokine secretion while simultaneously demonstrating limited allogenic reactivity, which subsequently led to the evaluation of therapeutic feasibility to treat inflammatory diseases. Although regulatory constraints have restricted MSC development pharmacologically, limited clinical studies have shown encouraging results using MSC infusions to treat systemic lupus erythematosus (SLE); but, more trials will have to be performed to conclusively determine the clinical efficacy of MSCs to treat SLE. Moreover, there are some data to suggest that MSCs possess tumorigenic potential and that the immunosuppressive influence can be dramatically affected by both donor variability and

Indexed as

autoimmunityemerging therapiesextracellular vesiclesinflammationmesenchymal stem cellssystemic lupus erythematosus

Identifiers

PMID28539924
PMCPMC5423896
OpenAlexW2612678922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.